Related Experiment Video
Updated: Sep 29, 2025
A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation
Published on: February 28, 2012
Experience with implantation of Select Secure® leads in paediatric patients
Mehmet Küçük1, Sevket Balli2, Huseyin Karadag2
1Department of Paediatric Cardiology, Samsun Training and Research Hospital, Samsun, Turkey.
Insights
The Select Secure® lead is safe and effective for paediatric patients needing cardiac devices. This transvenous pacing system demonstrated stable electrical performance and feasibility in children over midterm follow-up.
Area of Science:
- Cardiology
- Biomedical Engineering
- Paediatric Electrophysiology
Background:
- Cardiac device implantation in paediatric populations presents unique challenges.
- Evaluating novel pacing lead systems for safety and efficacy in children is crucial.
Purpose of the Study:
- To assess the safety, feasibility, and efficacy of the Select Secure® lead in a paediatric cohort.
- To document implantation techniques, complications, and acute/midterm performance.
Main Methods:
- A retrospective analysis of 42 paediatric patients (78 leads) implanted between 2014-2020.
- Evaluation of patient demographics, implantation details, sensing/pacing characteristics, and impedances.
- Monitoring for complications during acute and midterm follow-up (median 47 months).
Main Results:
- All 78 Select Secure® leads were successfully implanted, with ventricular leads anchored to the right ventricular midseptum.
- Implantation procedures were uneventful, with no major complications reported.
- Electrical parameters (sensing, pacing thresholds, impedance) remained stable throughout the follow-up period.
Conclusions:
- The Select Secure® transvenous pacing system is safe and feasible for paediatric cardiac device implantation.
- The system exhibits very stable electrical performance in the acute and midterm phases.
- This study supports the use of Select Secure® leads in paediatric patients.
Abstract:
Objective: In this study, we aimed to investigate the safety, feasibility and efficacy of Select Secure® lead in a pure paediatric cohort and to present our experience with implantation technique, complications, and acute and midterm performance of the lead.Method: From 2014 to 2020, 42 consecutive paediatric patients underwent a cardiac device implantation with Select Secure® lead system. Patient demographics, implantation technique, and locations, sensing and pacing characteristics, impedances and any complications at implant and follow-up were investigated.Results: The mean age and weight of patients were 11.2 ± 3.5 years and 34.7 ± 14.8 kg, respectively. A total of 78 Select Secure® leads were successfully implanted. All ventricular leads were successfully anchored to the right ventricular midseptum. Implantation procedures were uneventful in all patients. We showed that atrial and ventricular sensing, pacing thresholds, and impedance measurements did not change significantly and that adequate pacing parameters were achieved in our patients during a median follow-up period of 47 months (4 - 68). Atrial and ventricular sensing, pacing thresholds and impedance measurements remained almost the same during the study period.Conclusions: In this study, we found that the Select Secure® transvenous pacing system was safe and feasible in paediatric patients without any major complications and with very stable electrical performance in the acute and midterm period.
